FTRE Stock Forecast: Fortrea Holdings, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Fortrea Holdings, Inc. hold a median 12-month price target of $26 — +37.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Fortrea Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (93): Sales and profits are climbing, and climbing faster than before.
Volatility (18): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FTRE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FTRE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +37.5% from it.
Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Nov 2026 | TD Cowen | Maintains | Buy | $23 → $26 |
| 30 Oct 2026 | Barclays | Maintains | Overweight | $23 → $26 |
| 30 Oct 2026 | Citigroup | Maintains | Buy | $22 → $27 |
| 30 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $25 → $28 |
| 30 Oct 2026 | Truist Securities | Maintains | Buy | $26 → $29 |
| 20 Oct 2026 | UBS | Maintains | Neutral | $22 → $24 |
| 15 Oct 2026 | Deutsche Bank | Upgrade | Buy | $20 → $25 |
| 6 Oct 2026 | Barclays | Upgrade | Overweight | $22 → $23 |
| 30 Sept 2026 | UBS | Initiates | Neutral | $22 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | $19 → $23 |
| 31 July 2026 | Citigroup | Maintains | Buy | $20 → $22 |
| 30 July 2026 | Barclays | Maintains | Equal-Weight | $18 → $22 |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | $20 → $25 |
| 30 July 2026 | Truist Securities | Maintains | Buy | $19 → $26 |
| 13 July 2026 | Mizuho | Maintains | Neutral | $13 → $16 |
| 24 June 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 May 2026 | Mizuho | Maintains | Neutral | — |
| 6 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 May 2026 | Citigroup | Maintains | Buy | — |
| 14 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FTRE.
This page is one stock. Monday covers all of them.
FTRE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FTRE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Fortrea Holdings, Inc. returned +84.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FTRE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.7×
- Price / book
- 3.4×
- EV / EBITDA
- 22.8×
Cheaper than 74% of US stocks
Cheaper than 27% of US stocks
Cheaper than 17% of US stocks
- Revenue growth (YoY)
- −1.4%
- Earnings growth (YoY)
- —
- Gross margin
- 20.5%
- Operating margin
- 1.7%
- Net margin
- −2.6%
Higher than 26% of US stocks
Higher than 22% of US stocks
Higher than 46% of US stocks
Higher than 27% of US stocks
- Return on equity
- −12.3%
- Return on assets
- 1.0%
- Dividend yield
- —
Higher than 35% of US stocks
Higher than 49% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Fortrea Holdings, Inc. has a market value of $1.8B and an enterprise value of $2.7B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter shrank 4.5% year on year.
Net income over the same four quarters: −$85.2M, a −3.2% net margin.
Diluted earnings per share, trailing twelve months: −$0.91.
Free cash flow in the twelve months to 30 June 2026: $196.0M, after $31.8M of capital spending.
forward P/E: 16.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Fortrea Holdings, Inc. employs 14,000 people — $191K of revenue per employee.
Data provided by Twelve Data
FTRE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FTRE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Fortrea Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FTRE
What is the FTRE stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Fortrea Holdings, Inc. have a median 12-month price target of $26, with estimates ranging from $14 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FTRE stock a buy right now?
Of the 13 analysts covering Fortrea Holdings, Inc., 7 rate it a Buy, 3 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Fortrea Holdings, Inc. 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FTRE?
As at 21 Nov 2026, Fortrea Holdings, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).
Will FTRE stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +37.5% from the last close, and Ticker Nerd's factor model ranks Fortrea Holdings, Inc. 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FTRE stock forecast for 2030?
No analyst covering Fortrea Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $29 over the next 12 months.
How has FTRE stock performed over the past year?
Fortrea Holdings, Inc. returned +84.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Fortrea Holdings, Inc. do?
Fortrea Holdings Inc. is a global contract research organization that provides clinical development solutions to pharmaceutical, biotechnology, and medical device companies. Fortrea Holdings Inc. supports clients across the full clinical trial lifecycle, including Phase I through Phase IV studies, clinical pharmacology, data management, biostatistics, regulatory support, and post-approval evidence services.
About Fortrea Holdings, Inc.
Fortrea Holdings Inc. is a global contract research organization that provides clinical development solutions to pharmaceutical, biotechnology, and medical device companies. Fortrea Holdings Inc. supports clients across the full clinical trial lifecycle, including Phase I through Phase IV studies, clinical pharmacology, data management, biostatistics, regulatory support, and post-approval evidence services. The company offers flexible delivery models such as full-service, functional service provider, and hybrid arrangements to fit different development needs. Its services are used by biopharma and medtech customers seeking to manage complex trials, improve operational efficiency, and generate the clinical evidence needed to advance products through development and approval. Fortrea Holdings Inc. is headquartered in Durham, North Carolina, and operates as a specialized services provider in the life sciences market.
CEO Mr. Anshul Thakral · 14,000 employees · United States · https://www.fortrea.com